cabozantinib
Exelixis to Lay Off 130 Employees, Shut Down Pennsylvania Site in Post-Pandemic Downsizing
Exelixis; layoffs; Pennsylvania site closure; post-pandemic downsizing; biotech reorganization; Alameda headquarters; zanzalintinib; cabozantinib; King of Prussia
FDA clears Exelixis’ TKI for neuroendocrine tumours
CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor